Loading…

Challenge infection model for MERS-CoV based on naturally infected camels

Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. Thi...

Full description

Saved in:
Bibliographic Details
Published in:Virology journal 2020-06, Vol.17 (1), p.1-77, Article 77
Main Authors: Alharbi, Naif Khalaf, Ibrahim, Osman H, Alhafufi, Ali, Kasem, Samy, Aldowerij, Ali, Albrahim, Raed, Abu-obaidah, Ali, Alkarar, Ali, Bayoumi, Faisal Altaib, Almansour, Ali Mohammed, Aldubaib, Musaad, Al-Abdely, Hail M, Balkhy, Hanan H, Qasim, Ibrahim
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723
cites cdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723
container_end_page 77
container_issue 1
container_start_page 1
container_title Virology journal
container_volume 17
creator Alharbi, Naif Khalaf
Ibrahim, Osman H
Alhafufi, Ali
Kasem, Samy
Aldowerij, Ali
Albrahim, Raed
Abu-obaidah, Ali
Alkarar, Ali
Bayoumi, Faisal Altaib
Almansour, Ali Mohammed
Aldubaib, Musaad
Al-Abdely, Hail M
Balkhy, Hanan H
Qasim, Ibrahim
description Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.
doi_str_mv 10.1186/s12985-020-01347-5
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7d42c3225e5e45f3a54ec954440aebd4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627416503</galeid><doaj_id>oai_doaj_org_article_7d42c3225e5e45f3a54ec954440aebd4</doaj_id><sourcerecordid>A627416503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</originalsourceid><addsrcrecordid>eNptkkFv1DAQhSMEoqXwBzhF4kIPKfZ4HCcXpGpVYKVWSC0gbpZjT9KskrjYCaL_Hm93BV2EfLA1882z_fSy7DVnZ5xX5bvIoa5kwYAVjAtUhXySHXOFokCA708fnY-yFzFuGBNQqvp5diRASqgEP87Wq1szDDR1lPdTS3bu_ZSP3tGQtz7kVxfXN8XKf8sbE8nlqTeZeQlp5H7Pp6o1Iw3xZfasNUOkV_v9JPv64eLL6lNx-fnjenV-WVipcC5IOCKpDNQgKmddg9QiyfQyoUTdqhLA8VZI7pQiZ8qmUrUB62zjHCsViJNsvdN13mz0XehHE-61N71-KPjQaRPm3g6klUOwAkCSJJStMBLJ1hIRmaHGYdJ6v9O6W5qRnKVpTn87ED3sTP2t7vxPrZLziGUSeLsXCP7HQnHWYx8tDYOZyC9RA_JkNDJkCX3zD7rxS5iSVVsKq1pIVf2lOpM-kCz26V67FdXnJSjkpWQiUWf_odJyNPbWT9T2qX4wcHowkJiZfs2dWWLU65vrQxZ2rA0-xkDtHz8409vg6V3wdAqefgieluI35LXG8w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2414893578</pqid></control><display><type>article</type><title>Challenge infection model for MERS-CoV based on naturally infected camels</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Alharbi, Naif Khalaf ; Ibrahim, Osman H ; Alhafufi, Ali ; Kasem, Samy ; Aldowerij, Ali ; Albrahim, Raed ; Abu-obaidah, Ali ; Alkarar, Ali ; Bayoumi, Faisal Altaib ; Almansour, Ali Mohammed ; Aldubaib, Musaad ; Al-Abdely, Hail M ; Balkhy, Hanan H ; Qasim, Ibrahim</creator><creatorcontrib>Alharbi, Naif Khalaf ; Ibrahim, Osman H ; Alhafufi, Ali ; Kasem, Samy ; Aldowerij, Ali ; Albrahim, Raed ; Abu-obaidah, Ali ; Alkarar, Ali ; Bayoumi, Faisal Altaib ; Almansour, Ali Mohammed ; Aldubaib, Musaad ; Al-Abdely, Hail M ; Balkhy, Hanan H ; Qasim, Ibrahim</creatorcontrib><description>Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.</description><identifier>ISSN: 1743-422X</identifier><identifier>EISSN: 1743-422X</identifier><identifier>DOI: 10.1186/s12985-020-01347-5</identifier><identifier>PMID: 32552831</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Age ; Antibodies ; Antiviral agents ; Biohazards ; Camelidae ; Camelus dromedarius ; Challenge model ; Coronaviruses ; Disease control ; Disease transmission ; Dromedary camels ; Farms ; Health aspects ; Infections ; Medical research ; MERS-CoV ; Middle East respiratory syndrome ; Provinces ; Respiratory diseases ; Saudi Arabia ; Serology ; Seroprevalence ; Studies ; Vaccination ; Vaccine efficacy ; Vaccines ; Viral infections</subject><ispartof>Virology journal, 2020-06, Vol.17 (1), p.1-77, Article 77</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</citedby><cites>FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</cites><orcidid>0000-0002-6049-3383</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298446/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2414893578?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793</link.rule.ids></links><search><creatorcontrib>Alharbi, Naif Khalaf</creatorcontrib><creatorcontrib>Ibrahim, Osman H</creatorcontrib><creatorcontrib>Alhafufi, Ali</creatorcontrib><creatorcontrib>Kasem, Samy</creatorcontrib><creatorcontrib>Aldowerij, Ali</creatorcontrib><creatorcontrib>Albrahim, Raed</creatorcontrib><creatorcontrib>Abu-obaidah, Ali</creatorcontrib><creatorcontrib>Alkarar, Ali</creatorcontrib><creatorcontrib>Bayoumi, Faisal Altaib</creatorcontrib><creatorcontrib>Almansour, Ali Mohammed</creatorcontrib><creatorcontrib>Aldubaib, Musaad</creatorcontrib><creatorcontrib>Al-Abdely, Hail M</creatorcontrib><creatorcontrib>Balkhy, Hanan H</creatorcontrib><creatorcontrib>Qasim, Ibrahim</creatorcontrib><title>Challenge infection model for MERS-CoV based on naturally infected camels</title><title>Virology journal</title><description>Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.</description><subject>Age</subject><subject>Antibodies</subject><subject>Antiviral agents</subject><subject>Biohazards</subject><subject>Camelidae</subject><subject>Camelus dromedarius</subject><subject>Challenge model</subject><subject>Coronaviruses</subject><subject>Disease control</subject><subject>Disease transmission</subject><subject>Dromedary camels</subject><subject>Farms</subject><subject>Health aspects</subject><subject>Infections</subject><subject>Medical research</subject><subject>MERS-CoV</subject><subject>Middle East respiratory syndrome</subject><subject>Provinces</subject><subject>Respiratory diseases</subject><subject>Saudi Arabia</subject><subject>Serology</subject><subject>Seroprevalence</subject><subject>Studies</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral infections</subject><issn>1743-422X</issn><issn>1743-422X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkkFv1DAQhSMEoqXwBzhF4kIPKfZ4HCcXpGpVYKVWSC0gbpZjT9KskrjYCaL_Hm93BV2EfLA1882z_fSy7DVnZ5xX5bvIoa5kwYAVjAtUhXySHXOFokCA708fnY-yFzFuGBNQqvp5diRASqgEP87Wq1szDDR1lPdTS3bu_ZSP3tGQtz7kVxfXN8XKf8sbE8nlqTeZeQlp5H7Pp6o1Iw3xZfasNUOkV_v9JPv64eLL6lNx-fnjenV-WVipcC5IOCKpDNQgKmddg9QiyfQyoUTdqhLA8VZI7pQiZ8qmUrUB62zjHCsViJNsvdN13mz0XehHE-61N71-KPjQaRPm3g6klUOwAkCSJJStMBLJ1hIRmaHGYdJ6v9O6W5qRnKVpTn87ED3sTP2t7vxPrZLziGUSeLsXCP7HQnHWYx8tDYOZyC9RA_JkNDJkCX3zD7rxS5iSVVsKq1pIVf2lOpM-kCz26V67FdXnJSjkpWQiUWf_odJyNPbWT9T2qX4wcHowkJiZfs2dWWLU65vrQxZ2rA0-xkDtHz8409vg6V3wdAqefgieluI35LXG8w</recordid><startdate>20200617</startdate><enddate>20200617</enddate><creator>Alharbi, Naif Khalaf</creator><creator>Ibrahim, Osman H</creator><creator>Alhafufi, Ali</creator><creator>Kasem, Samy</creator><creator>Aldowerij, Ali</creator><creator>Albrahim, Raed</creator><creator>Abu-obaidah, Ali</creator><creator>Alkarar, Ali</creator><creator>Bayoumi, Faisal Altaib</creator><creator>Almansour, Ali Mohammed</creator><creator>Aldubaib, Musaad</creator><creator>Al-Abdely, Hail M</creator><creator>Balkhy, Hanan H</creator><creator>Qasim, Ibrahim</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6049-3383</orcidid></search><sort><creationdate>20200617</creationdate><title>Challenge infection model for MERS-CoV based on naturally infected camels</title><author>Alharbi, Naif Khalaf ; Ibrahim, Osman H ; Alhafufi, Ali ; Kasem, Samy ; Aldowerij, Ali ; Albrahim, Raed ; Abu-obaidah, Ali ; Alkarar, Ali ; Bayoumi, Faisal Altaib ; Almansour, Ali Mohammed ; Aldubaib, Musaad ; Al-Abdely, Hail M ; Balkhy, Hanan H ; Qasim, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Antibodies</topic><topic>Antiviral agents</topic><topic>Biohazards</topic><topic>Camelidae</topic><topic>Camelus dromedarius</topic><topic>Challenge model</topic><topic>Coronaviruses</topic><topic>Disease control</topic><topic>Disease transmission</topic><topic>Dromedary camels</topic><topic>Farms</topic><topic>Health aspects</topic><topic>Infections</topic><topic>Medical research</topic><topic>MERS-CoV</topic><topic>Middle East respiratory syndrome</topic><topic>Provinces</topic><topic>Respiratory diseases</topic><topic>Saudi Arabia</topic><topic>Serology</topic><topic>Seroprevalence</topic><topic>Studies</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alharbi, Naif Khalaf</creatorcontrib><creatorcontrib>Ibrahim, Osman H</creatorcontrib><creatorcontrib>Alhafufi, Ali</creatorcontrib><creatorcontrib>Kasem, Samy</creatorcontrib><creatorcontrib>Aldowerij, Ali</creatorcontrib><creatorcontrib>Albrahim, Raed</creatorcontrib><creatorcontrib>Abu-obaidah, Ali</creatorcontrib><creatorcontrib>Alkarar, Ali</creatorcontrib><creatorcontrib>Bayoumi, Faisal Altaib</creatorcontrib><creatorcontrib>Almansour, Ali Mohammed</creatorcontrib><creatorcontrib>Aldubaib, Musaad</creatorcontrib><creatorcontrib>Al-Abdely, Hail M</creatorcontrib><creatorcontrib>Balkhy, Hanan H</creatorcontrib><creatorcontrib>Qasim, Ibrahim</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Virology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alharbi, Naif Khalaf</au><au>Ibrahim, Osman H</au><au>Alhafufi, Ali</au><au>Kasem, Samy</au><au>Aldowerij, Ali</au><au>Albrahim, Raed</au><au>Abu-obaidah, Ali</au><au>Alkarar, Ali</au><au>Bayoumi, Faisal Altaib</au><au>Almansour, Ali Mohammed</au><au>Aldubaib, Musaad</au><au>Al-Abdely, Hail M</au><au>Balkhy, Hanan H</au><au>Qasim, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenge infection model for MERS-CoV based on naturally infected camels</atitle><jtitle>Virology journal</jtitle><date>2020-06-17</date><risdate>2020</risdate><volume>17</volume><issue>1</issue><spage>1</spage><epage>77</epage><pages>1-77</pages><artnum>77</artnum><issn>1743-422X</issn><eissn>1743-422X</eissn><abstract>Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><pmid>32552831</pmid><doi>10.1186/s12985-020-01347-5</doi><orcidid>https://orcid.org/0000-0002-6049-3383</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1743-422X
ispartof Virology journal, 2020-06, Vol.17 (1), p.1-77, Article 77
issn 1743-422X
1743-422X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7d42c3225e5e45f3a54ec954440aebd4
source Publicly Available Content (ProQuest); PubMed Central; Coronavirus Research Database
subjects Age
Antibodies
Antiviral agents
Biohazards
Camelidae
Camelus dromedarius
Challenge model
Coronaviruses
Disease control
Disease transmission
Dromedary camels
Farms
Health aspects
Infections
Medical research
MERS-CoV
Middle East respiratory syndrome
Provinces
Respiratory diseases
Saudi Arabia
Serology
Seroprevalence
Studies
Vaccination
Vaccine efficacy
Vaccines
Viral infections
title Challenge infection model for MERS-CoV based on naturally infected camels
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A16%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenge%20infection%20model%20for%20MERS-CoV%20based%20on%20naturally%20infected%20camels&rft.jtitle=Virology%20journal&rft.au=Alharbi,%20Naif%20Khalaf&rft.date=2020-06-17&rft.volume=17&rft.issue=1&rft.spage=1&rft.epage=77&rft.pages=1-77&rft.artnum=77&rft.issn=1743-422X&rft.eissn=1743-422X&rft_id=info:doi/10.1186/s12985-020-01347-5&rft_dat=%3Cgale_doaj_%3EA627416503%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2414893578&rft_id=info:pmid/32552831&rft_galeid=A627416503&rfr_iscdi=true